Literature DB >> 22382201

Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?

Claes G Tropé1, Mari B Elstrand, Berit Sandstad, Ben Davidson, Halldis Oksefjell.   

Abstract

OBJECTIVES: The aim of this study was to investigate the impact of surgical approach, the extent of surgery and chemotherapy on overall survival in patients with ovarian carcinoma (OC) stage IV.
METHODS: We retrospectively collected population-based data from the Norwegian Radium Hospital code registry on the diagnosis and surgery of 238 patients diagnosed with OC stage IV from 1996-2005. All patients received platinum-based chemotherapy. Surgical approach was registered as primary debulking surgery (PDS), interval debulking surgery (IDS) and delayed primary surgery (DPS). Surgery level was classified as radical surgery (RS), standard surgery (SS) or suboptimal surgery (SUBS). Univariate and multivariate analyses identified prognostic factors in PDS, IDS and DPS groups and subgroups.
RESULTS: There were no differences in overall survival between the PDS, IDS and DPS groups. Surgery level was significantly associated with overall survival in the whole cohort (p<0.001), the PDS and IDS groups, but not in the DPS group. More patients with RS achieved no residual tumour (RT), but overall survival was not superior compared to no RT in the SS group. In 66 patients with no RT there were no differences in overall survival between those who underwent PDS, IDS and DPS. Chemotherapy with platinum/paclitaxel tended to improve survival. RT, World Health Organisation (WHO) performance status and histology were prognostic factors for overall survival in the whole cohort.
CONCLUSION: No RT remains the objective, whether PDS, IDS or DPS is performed, and no differences in overall survival were found in the three treatment groups.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382201     DOI: 10.1016/j.ejca.2012.01.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Cutaneous Metastasis in Ovarian Cancer: Case Report and Literature Review.

Authors:  Danilo Coco; Silvana Leanza
Journal:  Maedica (Bucur)       Date:  2020-12

2.  Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.

Authors:  Ben Davidson; Arild Holth; Mai T P Nguyen; Claes G Tropé; Chuanyue Wu
Journal:  Gynecol Oncol       Date:  2012-10-22       Impact factor: 5.482

3.  Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer.

Authors:  Marianne J Rutten; Gabe S Sonke; Anneke M Westermann; Willemien J van Driel; Johannes W Trum; Gemma G Kenter; Marrije R Buist
Journal:  Obstet Gynecol Int       Date:  2015-05-27

4.  Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.

Authors:  M Mizuno; H Kajiyama; K Shibata; K Mizuno; M Kawai; T Nagasaka; F Kikkawa
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

5.  Skin metastases in epithelial ovarian and fallopian tube carcinoma.

Authors:  Isao Otsuka; Takuto Matsuura
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

Review 6.  Cutaneous Metastases in Ovarian Cancer.

Authors:  Isao Otsuka
Journal:  Cancers (Basel)       Date:  2019-09-02       Impact factor: 6.639

Review 7.  Outcome quality standards in advanced ovarian cancer surgery.

Authors:  Antoni Llueca; Anna Serra; Maria Teresa Climent; Blanca Segarra; Yasmine Maazouzi; Marta Soriano; Javier Escrig
Journal:  World J Surg Oncol       Date:  2020-11-25       Impact factor: 2.754

8.  Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer?

Authors:  Augusto Pereira; Javier F Magrina; Paul M Magtibay; Joao Siufi Neto; Daniela F S Siufi; Yu-Hui H Chang; Tirso Perez-Medina
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

9.  Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival.

Authors:  Yohann Dabi; Cyrille Huchon; Lobna Ouldamer; Sofiane Bendifallah; Pierre Collinet; Alexandre Bricou; Emile Daraï; Marcos Ballester; Vincent Lavoue; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2020-03-23       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.